Aetion
Dr. Scott Gottlieb is a Special Partner on the NEA healthcare investment team; he was a Venture Partner at NEA from 2007 to 2017 until being appointed the 23rd Commissioner of the U.S. FDA, where he served from 2017 to 2019.
In addition to his role as an investor, Dr. Gottlieb is a physician, policy expert, and advocate for healthcare entrepreneurship, innovation, and access. He is an elected member of the National Academy of Medicine and currently a Resident Fellow at the American Enterprise Institute (AEI) in Washington, DC. Dr. Gottlieb previously served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services.
Dr. Gottlieb is a graduate of the Mount Sinai School of Medicine and of Wesleyan University. In 2018 and again in 2019 Dr. Gottlieb was recognized by Fortune as one of "The World's 50 Greatest Leaders" and by Time as one of the “50 People Transforming Healthcare.”
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Aetion
9 followers
Aetion is a health care technology company that delivers real-world evidence for life sciences, payers, providers, and regulatory agencies. The Aetion Evidence Platform analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on treatments, costs, and outcomes. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs health care’s most critical decisions — what works best, for whom, and when — to guide treatment development, commercialization, and payment innovation into health care’s modern era.